Thorough QT study with ponesimod, a selective S1P1 receptor modulator

Trial Profile

Thorough QT study with ponesimod, a selective S1P1 receptor modulator

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2015

At a glance

  • Drugs Ponesimod (Primary) ; Moxifloxacin
  • Indications Graft-versus-host disease; Immunological disorders; Multiple sclerosis; Plaque psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Sep 2013 New trial record
    • 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top